Share on

Global Parkinson’s Disease Treatment Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Drug Class, Distribution Channel, Patient Care Setting, and Region - Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 7138
Pages: 175
Formats: report pdf report excel report power bi report ppt

Global Parkinson’s Disease Treatment Market Size (2022 to 2027)

Globally, the size of the Parkinson’s Disease Treatment Market is estimated to be growing at a CAGR of 5.97% from 2022 to 2027. The size of the market is predicted to value USD 6.39 billion by 2027 from USD 4.78 billion in 2022.

The slow development in stages of a neurological disorder that has features of the inexpressive face, the slowdown of spontaneous moments, walking with short steps, particular posture and muscle weakness which is caused by an area in the brain, and also low production of the neurotransmitter dopamine, is often termed as Parkinson's disease.


Y-O-Y growth in the aging population suffering from Parkinson's disease is the primary factor driving the global Parkinson’s disease treatment market growth.

Additionally, the increase in healthcare expenditure by the governments in research and development is the factor that drives the growth of the Parkinson's disease treatment market. The pharmacies that are available online are to grow faster during the forecast period. Robust health infrastructure and skilled neurologists’ professionals are the hospitals' driving factors, which propel the global Parkinson's disease treatment market.

Government authority or license, especially having the power to remove the others from applying branded drugs and the strong pipeline of products, is the opportunity provided during the forecast period.


Understanding what causes the complexity and diversity of Parkinson's disease is the main challenge for investigators or researchers. Investigators often work with local communities and caregivers to identify the problems of living with Parkinson's disease to translate scientific discoveries into patient care. The booklet named "Parkinson's Disease 2014: Advancing Research, Improving Lives" highlights the recent progress made in Parkinson's disease research and maps out the challenges and priorities. As the symptoms of PD progress, like walking, talking, swallowing, and completing other tasks, which can become challenging.

Healthcare providers, individuals with Parkinson's disease, caretakers, and other stakeholders together to assist the state of Parkinson's disease, define the key or main challenges, and set priorities for advancing Parkinson's Disease research. It can be challenging to consent from the prodromal and early stage of Parkinson's patients to give CSF samples for biomarker assessments in clinical trials.

Impact of COVID-19 on the global Parkinson’s disease treatment market:

Within a brief period, the world has faced significant changes due to COVID-19. The coronavirus (COVID-19) pandemic has significantly impacted the human body organs such as cardiac, diabetic, lungs, and kidneys. Though Parkinson's disease (PD) is not so rare compared to other health conditions, it affects millions worldwide. The indirect effects of the pandemic associated with the healthcare systems and clinical trials of Parkinson's Disease severely affect the PD patient's mental well-being creating significant barriers in managing the symptoms of PD. The COVID-19 has troubled PD patients in multiple ways. Aged people with advanced PD are more exposed to the respiratory pandemic. Several neurologists have faced challenges in maintaining efficient care for PD patients without exposing them to the risk of infection. PD patients struggled in maintaining their regular activities during the time of the lockdown period. Nonetheless, the market for Parkinson’s disease treatment is expected to perform well during the forecast period despite the situations imposed by the COVID-19.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Covered

By Drug Type, Distribution Channel, Patient Care Setting, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa


This research report on the global Parkinson's disease treatment market has been segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2026.

Parkinson’s Disease Treatment Market – By Drug Class:

  • Dopamine Receptor Antagonists   
    • Pramipexole
    • Ropinirole
    • Apomorphine
    • Rotigotine
  • Mono Amine Oxidase Inhibitors    
    • Selegiline
    • Rasagiline
  • Carbidopa
  • Anticholinergics   
  • Other Drug Classes 

Based on the drug class analysis, the Carbidopa segment is accounted to hold the largest share in the market, and the growth of this segment owes to the strength of the drug. The increasing aging population and regular increase of Parkinson’s diseases are considered to boost the market growth during the analysis period.

Parkinson’s Disease Treatment Market – By Distribution Channel:

Based on the distribution channel, the hospital pharmacies segment has the largest share in the segment. A growing number of patients visit the hospitals due to the availability of diagnostic laboratories, and the existence of expertise neurologists are propelling the market growth during the analysis period.

Parkinson’s Disease Treatment Market – By Patient Care Setting:

  • Clinics       
  • Hospitals  

Based on the Patient Care Settings analysis, the hospital segment is anticipated to account for the largest share in the market. Factors like robust healthcare infrastructure, reducing the need to visit pharmacies, and increasing hospital settings are leveling up the growth rate of the market.

Clinics hold a small share in the market due to the scarcity of neurologists, where most patients prefer hospitals.

Parkinson’s Disease Treatment Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Geographically, Europe was the leading market for Parkinson’s Disease Treatment in 2019, followed by North America and the Asia Pacific regions. The presence of established key players in this region, growing spending towards healthcare, the expected growth of Parkinson’s diseases in the region, and gene therapy has also increased.

North America is next to Europe to dominate the global Parkinson's disease treatment market due to reimbursement policies and regular increase of diseases, increasing expenditure on research and development activities, and regular FDA acceptances for novel pipeline drugs. The U.S. is projected to have the largest share in the market. Rise in older people population and availability of reimbursement policies and increasing consciousness among the population. Canada is behind the U.S. in leading the market due to recent product launches and many therapies among the product pipelines.

Due to the vast population base in the region, the Asia Pacific region is expected to have the fastest growth rate during the forecast period. The factors like developing several headache cases, rising public awareness regarding the diseases, enhanced distribution networks in pharma emerging nations, and massive demand for disease treatment in countries like China and Japan.

Latin America is expected to have steady and fixed growth in Parkinson’s treatment market during the estimated period. The market growth is attributed to supportive government policies, high sales in generic medicines, and a growing number of generic drug manufacturers.

The Middle East & Africa is expected to have limited growth in the market due to strength and extensive assumption in treating Parkinson’s disease treatment fueling market growth.


Some of the notable market participants leading the global Parkinson's disease treatment market profiled in this report are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).


  • In February 2020, Sun Pharma launched severe nodular acne management capsules in the US. It is launched for patients who are below 12 years of age and older. It can be taken with or without food.
  • In June 2019, Wockhardt got a booster from USFDA. The company has said that it has received a zero issue after inspecting bioequivalence from the US health regulator.
  • In October 2019, Sun Pharma launched Cequa to treat dry eye disease in the US. The company launched this ophthalmic solution called Cequa, used to treat dry eyes in the US market. 
  • In February 2020, Sun Pharma proposed to set up a production unit in Pharma City. The founder and managing director Dilip Shanghvi of Sun Pharma told Times Of India that they would manufacture Hyderabad's production company.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample